To evaluate treatment satisfaction (TS) and work productivity (WP) with two doses of IgPro20 (Hizentra) subcutaneous immunoglobulin (SCIG) versus placebo in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) during the PATH study.

Patients (n=172) received 0.2 or 0.4 g/kg IgPro20 weekly, or placebo. The Treatment Satisfaction Quality of Medication (TSQM) instrument assessed effectiveness, side effects, convenience, and overall satisfaction domains (ranging from 0, poorest; to 100, perfect satisfaction). The Work Productivity and Activity Impairment (WPAI) tool assessed absenteeism (Ab), work impairment (WI), activity impairment (AI), and WP loss domains (ranging from 0, best; to 100, worst). 

The observed trend in median TSQM scores at last post-dose observation (LPDO) was positive in the direction of treatment groups for overall satisfaction and effectiveness (placebo:  -11.1 points; 0.2 g/kg: -8.3 points; 0.4 g/kg: -5.6 points and placebo: -13.9 points; 0.2 g/kg: -5.6 points; 0.4 g/kg: -11.1 points respectively). WPAI AI, WI and WP loss scores were relatively stable in the IgPro20 groups compared with worsening on placebo at the LPDO (Median AI change score: 10% for placebo and 0% for each of 0.2 g/kg and 0.4 g/kg; median WI change score: 30% for placebo and 0% for each of 0.2 g/kg and 0.4 g/kg; median WP loss score: 22.2% for placebo, 2.5% for 0.2 g/kg, and 0% for 0.4 g/kg). There was no relevant difference across groups in change score on the Ab domain.

None of the treatment differences reached statistical significance; however, overall satisfaction and work impairment scores were more stable with IgPro20 (especially 0.4 g/kg) maintenance treatment compared to placebo. This supports the hypothesis that lower rates of relapse may be reflected in maintained satisfaction and work outcomes.